Your paper's title starts here:

International Journal of Science Vol.3 No.6 2016 ISSN: 1813-4890 Editorial: Nanomedicine for Treatment of Cancer
Chen Kang 1, Yuan Sun 2, a,* 1Division of Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH 2Department of Chemistry and Biochemistry, the Ohio State University, Columbus, OH 43210, *To whom correspondence should be addressed: Department of Chemistry and Biochemistry, The Ohio State University, Columbus, OH 43210, USA [email protected] Cancer is among the deadliest diseases faced by mankind, causing millions of deaths worldwide. [1] Decades of research into effective ways to fight cancer have provided therapeutic options such as chemotherapy, radiotherapy and curative surgery in order to control cancer progression and eradicate tumors. [2-5] However, due to the inherent complexity of cancer, it is still a tough task for scientists to truly cure this disease. Among available therapeutic alternatives, chemotherapy is considered the major approach in cancer therapy, as evidenced by the large quantity of prescriptions of chemotherapeutic drugs used in the clinic annually. While chemotherapeutic treatments provide benefits to many patients, the strong toxicity, poor tissue selectivity, narrow therapeutic windows and related drug resistance greatly limit the use of chemotherapeutic drugs and may adversely affect the quality of life of cancer patients. [6] In particular, the major cause of toxicity from chemotherapy is due to the off-target effects of the highly cytotoxic compounds used, which target physiological signaling pathways in non-tumor tissue and result in the death of healthy tissue. [7, 8] The off-target effects of therapeutic agents led to the concept of the "magic bullet", a term developed by German Nobel laureate Paul Ehrlich over 100 years ago and which describes the selective delivery of an active drug specifically to diseased tissues but not normal and healthy tissues.[9] The precise delivery of drugs would allow the use of smaller doses of pharmaceutical and chemotherapeutic agents in a more targeted approach that eliminates the off-target effects of these drugs, thereby holding the promise to overcome and cure cancer. Traditional pharmaceutical technology is limited in that it can only produce large, micrometer-sized delivery particles with limited capability for surface modification and targeting. Recent advances in nanotechnology have provided scientists with the ability to selectively generate nanoparticles of different sizes and properties for various objectives. Using top-down or bottom-up nanoparticle synthesis methods, scientists are now able to manipulate the size, shape, and internal and external physicochemical properties of nanoparticles. In addition, novel techniques are providing insight into mechanisms for drug loading onto these nanoparticles.[10, 11] Nanoparticles provide a huge promise for cancer therapy as nanoparticles show an enhanced permeability and retention (EPR) effect which permits these nanoparticles to specifically target tumor cells as well as accumulate in the tumor due to the leaky nature of tumor vasculature. Both non-covalent encapsulation and covalent conjugation have been exploited to load active drugs into nanoparticles. In non-covalent encapsulation, drug molecules are loaded into nanoparticles by non-covalent bonding such as hydrogen bonding and π-π interaction. This offers the advantages of allowing the adjustment of the dosage ratio as well as the ability to deliver multiple drugs simultaneously as combination therapy, an approach that has been shown to improve the efficacy of cancer treatment.[12] However, the weak, non-covalent nature of the drug-nanoparticle linkage may lead to instability in the kinetics of drug release, leading to a rapid "burst" of drugs from nanoparticles and imprecise drug loading percentage. In comparison, covalent conjugates in which the drugs and nanoparticles are chemically bonded together enable the generation of a drug delivery vehicle having International Journal of Science Vol.3 No.6 2016 ISSN: 1813-4890 a predictable drug release profile which can be adjusted by either the concentration of conjugates or the amount of attached drugs. [4, 13-15] Therapeutic drug-nanoparticle conjugates are being developed and used in the clinic. One of the most successful examples of therapeutic nanoparticles is Abraxane® which uses albumin as a delivery vehicle for paclitaxel.[16] Paclitaxel is a drug from Taxane family that suppresses microtubule dynamics during cancer cell division. Abraxane® has an average nanoparticle size of about 130 nm and has been approved U.S. Food and Drug Administration (FDA) for the treatment of breast cancer, lung cancer and pancreatic cancer. While this is one example of nanoparticles in cancer therapy, there are currently more than 200 nanomedicines that are either approved for use or are in different stages of clinical trials. The field of nanomedicine is still young. While great achievements have been accomplished in this field, there are still many essential questions for scientists to address regarding nanomedicine and its application in cancer therapy. These questions include the choice of biocompatible materials, the immunological response from delivery vehicles and the potential systemic toxicities of nanosized medicines.[17, 18] Answering these questions will allow the development of nanomedicine and will lead to enhanced targeting and treatment of cancer and other diseases. References:
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: A Cancer Journal for Clinicians, [2] Livingston RB. Single agents in cancer chemotherapy. Springer Science & Business Media 2012. [3] Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nature Reviews Cancer, 2012; 12: 237-251. [4] Kang C, Sun Y, Wang M, Cheng X. Nanosized Camptothecin Conjugates for Single and Combined Drug Delivery. European Journal of BioMedical Research, 2016; 2: 8-14. [5] Zhou Y, Xu X, Sun Y, Wang H, Sun H, You Q. Synthesis, cytotoxicity and topoisomerase II inhibitory activity of lomefloxacin derivatives. Bioorganic & medicinal chemistry letters, 2013; 23: 2974-2978. [6] Plenderleith IH. Treating the treatment: toxicity of cancer chemotherapy. Canadian Family Physician, 1990; 36: 1827. [7] Sun Y, Kang C, Zhang A, Liu F, Hu J, Zhong X, Xie J. Co-delivery of dual-drugs with nanoparticle to overcome multidrug resistance. European Journal of BioMedical Research, 2016; 2: 12-18. [8] Guo XK, Sun HP, Shen S, Sun Y, Xie FL, Tao L, Guo QL, Jiang C, You QD. Synthesis and evaluation of gambogic acid derivatives as antitumor agents. Part III. Chemistry & biodiversity, 2013; 10: 73-85. [9] Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. Journal of Controlled Release, 2011; 153: 198. [10]Lee S-H, Roichman Y, Yi G-R, Kim S-H, Yang S-M, van Blaaderen A, van Oostrum P, Grier DG. Characterizing and tracking single colloidal particles with video holographic microscopy. Optics Express, 2007; 15: 18275-18282. [11]Wang C, Zhong X, Ruffner DB, Stutt A, Philips LA, Ward MD, Grier DG. Holographic characterization of protein aggregates. Journal of pharmaceutical sciences, 2016; 105: 1074-1085. [12]Fenske DB, Chonn A, Cullis PR. Liposomal nanomedicines: an emerging field. Toxicologic pathology, 2008; 36: 21-29. [13]Kim SH, Kaplan JA, Sun Y, Shieh A, Sun HL, Croce CM, Grinstaff MW, Parquette JR. The Self‐Assembly of Anticancer Camptothecin–Dipeptide Nanotubes: A Minimalistic and High Drug Loading Approach to Increased Efficacy. Chemistry-A European Journal, 2015; 21: 101-105. [14]Sun Y, Kaplan JA, Shieh A, Sun H-L, Croce CM, Grinstaff MW, Parquette JR. Self-assembly of a 5-fluorouracil-dipeptide hydrogel. Chemical Communications, 2016; 52: 5254-5257. International Journal of Science Vol.3 No.6 2016 ISSN: 1813-4890 [15]Sun Y, Shieh A, Kim SH, King S, Kim A, Sun HL, Croce CM, Parquette JR. The self-assembly of a camptothecin-lysine nanotube. Bioorg Med Chem Lett, 2016; 26: 2834-8. [16]Green M, Manikhas G, Orlov S, Afanasyev B, Makhson A, Bhar P, Hawkins M. Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Annals of Oncology, 2006; 17: 1263-1268. [17]Linkov I, Satterstrom FK, Corey LM. Nanotoxicology and nanomedicine: making hard decisions. Nanomedicine: Nanotechnology, Biology and Medicine, 2008; 4: 167-171. [18]Yung BC, Li J, Zhang M, Cheng X, Li H, Yung EM, Kang C, Cosby LE, Liu Y, Teng L, Lee RJ. Lipid Nanoparticles Composed of Quaternary Amine–Tertiary Amine Cationic Lipid Combination (QTsome) for Therapeutic Delivery of AntimiR-21 for Lung Cancer. Molecular Pharmaceutics, 2016; 13: 653-662.


Antibiotic susceptibility of potentiAlly probiotic LactobaciLLus strAins JunhuA hAna, DAhuAn chena, shAnshAn lic, Xingfeng lia, Wen-Wen Zhoud, bolin ZhAngb,*, yingmin JiAa,* aCollege of Biological Science and Engineering, Hebei University of Science and Technology, Shijiazhuang, Heibei, 050018, China bSchool of Biological Science and Biotechnology, Beijing Forestry University, Beijing, 100083, China

The broad-host-range plasmid psfa231 isolated from petroleum-contaminated sediment represents a new member of the proma plasmid family

1,2, 3, Yafei Wang 1, , 1,2, Shan Yang 1, 1 and1* 1 State Key Laboratory of Forest and Soil Ecology, Institute of Applied Ecology, Chinese Academy of Sciences, Shenyang, China2 College of Resources and Environment, University of Chinese Academy of Sciences, Beijing, China3 Department of Biological Sciences, Institute for Bioinformatics and Evolutionary Studies, University of Idaho, Moscow, ID, USA

Copyright © 2008-2016 No Medical Care